Ascendis Pharma AS (ASND)
129.81
+7.17
(+5.85%)
USD |
NASDAQ |
Nov 22, 16:00
134.49
+4.68
(+3.61%)
After-Hours: 20:00
Ascendis Pharma Revenue (Annual): 288.75M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 288.75M |
| December 31, 2022 | 53.97M |
| December 31, 2021 | 9.203M |
| December 31, 2020 | 7.940M |
| December 31, 2019 | 14.97M |
| December 31, 2018 | 12.49M |
| Date | Value |
|---|---|
| December 31, 2017 | 1.733M |
| December 31, 2016 | 5.098M |
| December 31, 2015 | 9.009M |
| December 31, 2014 | 18.60M |
| December 31, 2013 | 27.10M |
| December 31, 2012 | 20.03M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
7.940M
Minimum
2020
288.75M
Maximum
2023
74.97M
Average
14.97M
Median
2019
Revenue (Annual) Benchmarks
| Novo Nordisk AS | 33.72B |
| Evaxion Biotech AS | 0.073M |
| Akari Therapeutics PLC | -- |
| Biodexa Pharmaceuticals PLC | 0.4741M |
| TC BioPharm (Holdings) PLC | -- |